세포 치료 시장 : 유형별, 치료법별, 투여 방법별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Cell Therapy Market is projected to grow by USD 14.73 billion at a CAGR of 12.59% by 2032.

Cell Therapy Market Executive Summary

Cell therapy is moving from a breakthrough modality into a core pillar of advanced healthcare, spanning CAR T-cell therapy, tumor-infiltrating lymphocyte therapy, hematopoietic stem cell transplantation, mesenchymal stromal cell applications, induced pluripotent stem cell platforms, and emerging allogeneic cell therapy programs. Since the first U.S. FDA approval of a CAR T-cell therapy in 2017, regulators have authorized multiple cellular medicines for hematologic malignancies, and the 2024 U.S. approval of the first TIL therapy for advanced melanoma further validated the clinical and therapeutic relevance of engineered and expanded living medicines.

The cell therapy market is being shaped by strong demand in oncology, rising investment in autoimmune and inflammatory disease programs, advances in cell therapy manufacturing, and the need for scalable, quality-controlled supply chains. For industry leaders, the most defensible opportunities are forming where clinical efficacy, durable patient response, manufacturing reliability, reimbursement readiness, and real-world evidence generation converge.

Transformative Shifts in the Cell Therapy Landscape

The cell therapy landscape is shifting from individualized, hospital-centered treatment pathways toward more industrialized platforms that can support broader patient access. Autologous CAR T-cell therapy remains a benchmark for clinical value in blood cancers, but long vein-to-vein timelines, complex logistics, and high production costs are accelerating development of allogeneic, in vivo, and automated manufacturing models.

Scientific progress is also widening the addressable disease base. Cell therapies are advancing beyond hematologic malignancies into solid tumors, autoimmune diseases, rare genetic disorders, regenerative medicine, and transplant-related indications. At the same time, regulators are emphasizing potency assays, comparability, long-term follow-up, and post-market safety surveillance, making evidence quality a central competitive differentiator.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is becoming a cumulative force across the cell therapy value chain by improving target discovery, donor and patient stratification, process development, quality analytics, and clinical trial design. AI-enabled image analysis, multi-omics modeling, and machine learning applied to manufacturing data can help identify potency markers, predict batch variability, and support faster root-cause analysis when deviations occur.

The impact is especially important for cell therapy manufacturing, where living products are sensitive to starting material quality, culture conditions, and logistics. AI does not replace regulatory-grade validation, but it can strengthen process control, reduce failed batches, and support adaptive trial enrollment when integrated with compliant data governance, explainable models, cybersecurity controls, and human oversight.

Key Regional Insights for Cell Therapy

North America remains one of the most mature regions for cell therapy, led by the United States through FDA-approved CAR T-cell therapies, a deep biotechnology financing ecosystem, strong academic medical centers, and established specialty treatment networks. Canada is also advancing through hospital-based cell therapy programs, public research initiatives, and regenerative medicine collaborations, although manufacturing scale, payer coordination, and geographic access remain key priorities.

Europe benefits from the European Medicines Agency's advanced therapy medicinal product framework and strong translational research clusters across Germany, France, Italy, Spain, and the United Kingdom. The European Union's centralized regulatory pathway supports cross-border authorization, while country-level health technology assessment, hospital exemption practices, national pricing systems, and reimbursement processes continue to shape launch sequencing and patient access.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets invest in regenerative medicine, oncology innovation, clinical trial capacity, and domestic manufacturing capabilities. China has built a large clinical development base for CAR T-cell therapy, Japan operates a regenerative medicine regulatory framework designed to support conditional and time-limited access, and South Korea and Australia are strengthening advanced therapy infrastructure through biomanufacturing, translational research, and internationally credible clinical trial systems.

Latin America, the Middle East, and Africa are at earlier but increasingly strategic stages of adoption. Brazil and Mexico are regional anchors for clinical research, transplant capabilities, and specialty oncology care in Latin America. GCC countries are investing in medical hubs, genomics, precision medicine infrastructure, and specialized hospitals, while African markets are gradually building capacity through oncology centers, hematopoietic stem cell transplant programs, public health partnerships, and international collaborations focused on equitable access.

Key Group Insights Across Global Cell Therapy Markets

The European Union and G7 economies are central to cell therapy commercialization because they combine advanced regulatory systems, high healthcare spending, robust intellectual property protection, established pharmacovigilance practices, and mature clinical trial networks. These markets often set global expectations for quality, comparability, long-term safety follow-up, reimbursement evidence, and health economic value demonstration for advanced therapy medicinal products.

BRICS countries are increasingly important to cell therapy development due to large patient populations, rising biomanufacturing capacity, expanding oncology infrastructure, and government support for biotechnology self-reliance. China and India are particularly influential within BRICS, with China leading in cell therapy clinical activity and India expanding cost-efficient bioprocessing, hospital networks, domestic innovation, and access-oriented treatment models.

ASEAN offers a diverse growth corridor where Singapore acts as a biomedical hub and Thailand, Malaysia, Indonesia, Vietnam, and the Philippines continue building capacity in specialty care, clinical research, and regenerative medicine services. GCC markets are investing in high-acuity medical infrastructure, genomics-led healthcare, and medical tourism capabilities, while NATO members overlap significantly with advanced North American and European research ecosystems that support resilient supply chains, clinical collaboration, quality standards, and regulatory alignment.

Key Country Insights in Cell Therapy

The United States leads the global cell therapy market through FDA approvals, academic medical centers, clinical trial activity, specialized treatment networks, and advanced manufacturing capacity. Canada complements this ecosystem with strong public research institutions, cell therapy networks, and hospital-based programs, while Mexico is gaining relevance through specialty care, clinical capabilities, and manufacturing-adjacent opportunities in North America. Brazil is Latin America's most important cell therapy hub due to its research hospitals, transplant expertise, public health system experience, and expanding oncology infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major centers for advanced therapy research, clinical adoption, regulatory engagement, and reimbursement evaluation. Germany and France provide strong biomanufacturing and hospital networks, the United Kingdom remains influential through innovation pathways, academic excellence, and early-access mechanisms, while Italy and Spain contribute significant transplant, oncology, and hospital-based advanced therapy expertise. Russia maintains scientific capabilities in cell-based research and transplant medicine but faces greater international collaboration, procurement, and supply chain constraints.

In Asia-Pacific, China has become a major center for CAR T-cell therapy development and clinical trials, supported by large patient access, hospital networks, and domestic innovation policies, while India is expanding affordable biotechnology platforms, stem cell research governance, and hospital-based advanced care. Japan's regenerative medicine framework and established pharmaceutical sector support translation, South Korea is investing in biomanufacturing, cell therapy startups, and regulatory modernization, and Australia provides a strong clinical trial environment, translational research networks, and high regulatory credibility.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturability as early as clinical design. Programs with clear potency assays, scalable closed-system manufacturing, robust chain-of-identity and chain-of-custody controls, validated cryopreservation strategies, and standardized release testing are better positioned for regulatory review, commercialization, and reliable patient delivery.

Organizations should also build reimbursement evidence from the start by linking clinical endpoints to durability, quality of life, hospital utilization, safety management, and total cost of care. Partnerships with academic centers, contract manufacturers, data platforms, logistics specialists, and payer stakeholders can accelerate development while reducing execution risk in a market where scientific success must be matched by operational excellence.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with established standards for market intelligence. Inputs include regulatory agency disclosures, clinical trial registries, peer-reviewed literature, public health authority updates, patent and product approval information, reimbursement policy documents, and validated industry sources covering cell therapy, CAR T-cell therapy, stem cell therapy, regenerative medicine, and advanced therapy medicinal products.

The analysis emphasizes triangulation across scientific, regulatory, commercial, manufacturing, and regional indicators. Market interpretations are derived from observable evidence such as therapy approvals, clinical development activity, manufacturing investments, reimbursement pathways, treatment infrastructure, safety requirements, and regional policy frameworks rather than unsupported claims.

Conclusion

Cell therapy is entering a decisive phase in which clinical validation, manufacturing scale, AI-enabled process intelligence, and reimbursement evidence will determine market leadership. The sector's strongest momentum remains in oncology, but autoimmune disease, regenerative medicine, solid tumor research, and allogeneic platforms are widening the long-term opportunity for advanced cellular medicines.

Organizations that combine scientific differentiation with operational discipline will be best positioned to capture value. As global regions build capacity and regulators refine expectations, the next phase of the cell therapy market will reward stakeholders that can deliver safe, effective, accessible, quality-controlled, and economically sustainable living medicines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Market, by Type

• 7.1. Non-stem Cells
  • 7.1.1. CAR-T Cells
  • 7.1.2. Dendritic Cells
  • 7.1.3. NK Cells
• 7.2. Stem Cells
  • 7.2.1. Embryonic Stem Cells
  • 7.2.2. Hematopoietic Stem Cell
  • 7.2.3. Mesenchymal Stem Cell

8. Cell Therapy Market, by Therapy Type

• 8.1. Allogenic
• 8.2. Autologous

9. Cell Therapy Market, by Mode of Administration

• 9.1. Intramuscular
• 9.2. Intratumoral
• 9.3. Intravenous

10. Cell Therapy Market, by Application

• 10.1. Autoimmune Disorders
  • 10.1.1. Multiple Sclerosis
  • 10.1.2. Rheumatoid Arthritis
• 10.2. Cancer Treatment
  • 10.2.1. Hematologic Malignancies
  • 10.2.2. Solid Tumors
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial Infections
  • 10.3.2. Viral Infections
• 10.4. Regenerative Medicine

11. Cell Therapy Market, by End User

• 11.1. Academic & Research Institutes
• 11.2. Clinics
• 11.3. Commercial Laboratories
• 11.4. Hospitals

12. Cell Therapy Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Cell Therapy Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Cell Therapy Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Allogene Therapeutics, Inc.
• 16.2. Anterogen Co., Ltd.
• 16.3. Astellas Pharma Inc.
• 16.4. Athersys, Inc.
• 16.5. BioNTech SE
• 16.6. Bristol-Myers Squibb Company
• 16.7. Castle Creek Biosciences, Inc.
• 16.8. Catalent, Inc.
• 16.9. FUJIFILM Holdings Corporation
• 16.10. Gilead Sciences, Inc.
• 16.11. JCR Pharmaceuticals Co., Ltd.
• 16.12. Kolon TissueGene, Inc.
• 16.13. Lonza Group Ltd.
• 16.14. Lovance Biotherapeutics, Inc.
• 16.15. Medipost Co., Ltd.
• 16.16. Mesoblast Ltd.
• 16.17. Novartis AG
• 16.18. Pfizer Inc.
• 16.19. Sartorius AG
• 16.20. Stemedica Cell Technologies, Inc.
• 16.21. Stempeutics Research Pvt. Ltd.
• 16.22. Takeda Pharmaceutical Company Limited
• 16.23. TegoScience
• 16.24. Thermo Fisher Scientific, Inc.
• 16.25. Vericel Corporation